Cart
sales@molnova.com
KN1022
CAS No. 205255-11-4
KN1022( —— )
Catalog No. M35326 CAS No. 205255-11-4
KN1022 is an inhibitor of phosphorylation of platelet-derived growth factor (PDGF) receptor with IC50 of 0.26 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 178 | Get Quote |
|
| 5MG | 255 | Get Quote |
|
| 10MG | 374 | Get Quote |
|
| 25MG | 545 | Get Quote |
|
| 50MG | 762 | Get Quote |
|
| 100MG | 1017 | Get Quote |
|
| 500MG | 2034 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameKN1022
-
NoteResearch use only, not for human use.
-
Brief DescriptionKN1022 is an inhibitor of phosphorylation of platelet-derived growth factor (PDGF) receptor with IC50 of 0.26 μM.
-
DescriptionKN1022 an inhibitor of phosphorylation of platelet-derived growth factor receptor (PDGFR) with IC50 of 0.24 μM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDGFR
-
RecptorPDGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number205255-11-4
-
Formula Weight438.44
-
Molecular FormulaC21H22N6O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO(C)C1=CC=2C(=NC=NC2C=C1OC)N3CCN(C(NC4=CC=C(N(=O)=O)C=C4)=O)CC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kenji Matsuno, et al. Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives. J Med Chem. 2002 Jul 4;45(14):3057-66.?
molnova catalog
related products
-
Olaratumab
Olaratumab(IMC-3G3) is a human monoclonal IgG1 antibody against platelet-derived growth factor receptor alpha (PDGFRα), which has antitumor effects and can be used to study advanced soft tissue sarcomas.
-
Rinucumab
Rinucumab (REGN 2176) is an anti-platelet-derived growth factor (PDGF) IgG4-like monoclonal antibody that acts by binding to the PDGF-β receptor and can be used to study age-related macular degeneration.
-
Axitinib
Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.
